Abstract
Background and Objective: B lymphocyte stimulator (BLyS) was considered as a novel adipokine in mice inducing low-grade inflammation and insulin resistance in obesity. Therefore, our aim was to examine (1) whether BLyS expression in human adipocytes in vivo differs between lean and obese ± insulin resistant subjects, (2) whether BLyS serum concentrations are dysregulated in obesity ± insulin resistance, (3) whether BLyS responds to different weight loss therapies and (4) whether inhibition of BLyS in humans in vivo by a neutralizing antibody (belimumab) alters insulin sensitivity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
